Galderma's five R&D centers are located in France, Sweden, Switzerland, the United States and Japan and are playing a key role in the the discovery and development of innovative medical solutions for the global dermatology market.
With 270 000 square feet, Galderma's research center in Sophia Antipolis, France is the largest dermatology research site in the world. The Sophia Antipolis center hosts Galderma's in-house research, pre clinical and core development activities. It is supported by clinical development centers in New Jersey, USA, Switzerland and Japan.
These state-of-the-art research centers have led to the development of several breakthrough molecules such as adapalene, a novel retinoid-like molecule that was developed after more than 10 years of research and has been clinically studied in over 6,000 patients. This active ingredient is at the heart of Differin® Gel and Epiduo® Gel formulations. Over the last 15 years we have also focused on addressing previously unmet needs of patients with innovative products for many skin diseases.
The global Aesthetic Center of Excellence of Uppsala, Sweden is dedicated to Aesthetic & Corrective treatments. Its 80 researchers have built extensive expertise.
More than 600 employees in the scientific division.